In a 30‑year‑old male patient treated with ceftriaxone and doxycycline for an acute gastrointestinal infection, who now shows elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) with normal bilirubin, what is the most likely cause of the transaminase rise?

Drug-Induced Liver Injury from Ceftriaxone

The most likely cause of the rising transaminases in this patient is ceftriaxone-induced hepatotoxicity, given the temporal relationship between antibiotic administration and enzyme elevation, the hepatocellular injury pattern (ALT 193, AST 150), and the exclusion of viral hepatitis and other infectious causes 1, 2, 3.

Clinical Reasoning

This 30-year-old male presents with a classic scenario for drug-induced liver injury (DILI):

• Temporal association: Transaminases rose significantly after 5 days of ceftriaxone therapy (from SGPT 60/SGOT 50 to SGPT 193/SGOT 150)
• Hepatocellular pattern: The ALT/AST elevation with normal bilirubin (1.04 mg/dL) indicates hepatocellular injury rather than cholestatic injury 4
• Comprehensive viral exclusion: HBV, HCV, HAV, HEV all negative, ruling out viral hepatitis as the primary cause
• Clinical improvement: Fever resolved and diarrhea improving, suggesting the underlying infection is controlled

Why Ceftriaxone is the Culprit

Ceftriaxone-induced liver injury is well-documented, though often underrecognized 3, 5, 6:

• Can occur at any age, with onset typically within 0.5-47 days of drug initiation 3
• Adults predominantly develop cholestatic or mixed injury patterns, but hepatocellular injury occurs in approximately 30-40% of cases 3
• Peak ALT values in documented cases range from 228.5 to 8098 U/L 3
• The injury pattern can be mild and asymptomatic in 73% of cases 3
• 97% of patients recover completely after drug discontinuation 3

The FDA drug label for ceftriaxone does not specifically list hepatotoxicity as a common adverse effect 7, which contributes to underrecognition of this complication.

Alternative Causes Considered and Excluded

Doxycycline hepatotoxicity is possible but less likely:

• Doxycycline rarely causes significant hepatocellular injury at standard doses
• The temporal pattern more strongly implicates ceftriaxone, which was started simultaneously

E. coli bacteremia/sepsis-related hepatic dysfunction:

• Blood cultures are negative, making systemic bacterial infection unlikely
• The patient is clinically improving (fever resolved, diarrhea decreasing)
• Sepsis-associated liver injury typically presents with higher AST than ALT and often includes hyperbilirubinemia 4

Autoimmune hepatitis 8, 9, 8:

• Can present acutely with elevated transaminases
• However, the temporal relationship with drug administration and absence of typical features (hypergammaglobulinemia not mentioned, only 36% lymphocytes) make this less likely
• Would require autoantibody testing (ANA, ASMA, anti-LKM) and potentially liver biopsy for confirmation

Immediate Management Recommendations

Discontinue ceftriaxone immediately 10, 1, 2:

• Drug-induced hepatitis requires prompt cessation of the offending agent
• The threshold for action is ALT ≥3× ULN with symptoms OR ≥5× ULN without symptoms 10
• This patient has ALT approximately 3-4× ULN (assuming ULN ~50 U/L)

Switch to alternative antibiotic coverage:

• Continue doxycycline alone if adequate for the clinical scenario
• Consider azithromycin or fluoroquinolone if broader coverage needed
• Avoid other cephalosporins due to potential cross-reactivity

Monitor liver function closely:

• Repeat LFTs in 48-72 hours
• Expect gradual normalization over 1-2 weeks after drug discontinuation 2, 3
• Monitor for symptoms of hepatotoxicity (nausea, vomiting, abdominal pain, jaundice)

Risk Factors Present in This Patient

Recent data suggests specific risk factors for ceftriaxone-associated liver dysfunction 11:

• Baseline ALT ≥11 U/L (this patient had SGPT 60)
• Elevated inflammatory markers (CRP ≥5.9 mg/dL)
• Patients with both risk factors have a 50% incidence of liver dysfunction versus 0% with neither 11

Critical Pitfalls to Avoid

1. Do not continue ceftriaxone while "monitoring" liver enzymes—this risks progression to severe hepatotoxicity
2. Do not assume viral hepatitis is the only cause of acute transaminase elevation in febrile patients
3. Do not overlook drug-induced injury when multiple antibiotics are used simultaneously
4. Do not rechallenge with ceftriaxone in the future—document this as a drug allergy/adverse reaction 1

Expected Clinical Course

With immediate ceftriaxone discontinuation 2, 3, 5:

• Transaminases should peak within 24-48 hours
• Gradual decline over 7-14 days
• Complete normalization expected within 2-4 weeks
• Prognosis is excellent (97% full recovery) 3

If transaminases continue rising or bilirubin increases significantly after drug cessation, consider alternative diagnoses including autoimmune hepatitis or other drug reactions, and obtain hepatology consultation.